{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:17:52Z","timestamp":1789103872209,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000850","name":"National Heart and Lung Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jchf.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T16:25:06Z","timestamp":1649262306000},"page":"369-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart\u00a0Failure"],"prefix":"10.1016","volume":"10","author":[{"given":"Kangyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2022.01.010_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood\u00a0pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2022.01.010_bib2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib3","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/HJH.0000000000002094","article-title":"Effects of blood pressure-lowering drugs in heart failure: a systematic review and meta-analysis of\u00a0randomized controlled trials","volume":"37","author":"Pinho-Gomes","year":"2019","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jchf.2022.01.010_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","article-title":"Blood pressure and heart failure","volume":"26","author":"Oh","year":"2020","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.jchf.2022.01.010_bib5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","article-title":"Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction","volume":"116","author":"Nichols","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2022.01.010_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/HYPERTENSIONAHA.107.090290","article-title":"Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study","volume":"50","author":"Mancia","year":"2007","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.jchf.2022.01.010_bib7","article-title":"Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension","volume":"6","author":"Doumas","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2022.01.010_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202359","article-title":"Time spent at blood pressure target and the risk of death and cardiovascular diseases","volume":"13","author":"Chung","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2022.01.010_bib9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.01.010_bib10","first-page":"543","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2022.01.010_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCHEARTFAILURE.111.961441","article-title":"Dilemmas of blood pressure management for heart failure prevention","volume":"4","author":"Georgiopoulou","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2022.01.010_bib12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A\u00a0trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2022.01.010_bib15","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0002-9149(99)80766-8","article-title":"Design of the Beta-Blocker Evaluation Survival Trial (BEST)","volume":"75","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2022.01.010_bib16","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.01.010_bib17","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.01.010_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A\u00a0method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jchf.2022.01.010_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib21","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.01.010_bib22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.01.010_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.805","article-title":"Prognostic value of long-term blood pressure changes in patients with chronic heart failure","volume":"19","author":"Schmid","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2022.01.010_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/hrt.2007.134973","article-title":"Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure","volume":"95","author":"Raphael","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2022.01.010_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2019.9811","article-title":"Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes","volume":"322","author":"Yang","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2022.01.010_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/HYPERTENSIONAHA.110.162255","article-title":"The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994","volume":"57","author":"Muntner","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.01.010_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/HYPERTENSIONAHA.114.03903","article-title":"Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis","volume":"64","author":"Diaz","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.01.010_bib28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/HYPERTENSIONAHA.120.16757","article-title":"Visit-to-visit blood pressure variability and clinical outcomes in patients with heart failure with preserved ejection fraction","volume":"77","author":"Wei","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.01.010_bib29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.112.202143","article-title":"Within-subject blood pressure level \u2014 not variability \u2014 predicts fatal and nonfatal outcomes in a general population","volume":"60","author":"Schutte","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.01.010_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103169","article-title":"Randomised double-blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trial","volume":"9","author":"Hara","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2022.01.010_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/HYPERTENSIONAHA.117.09788","article-title":"Visit-to-visit office blood pressure variability and cardiovascular outcomes in SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"70","author":"Chang","year":"2017","journal-title":"Hypertension"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:24Z","timestamp":1761973224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177922000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2213177922000750"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.01.010","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}